Endogenous retrovirus analyses in myalgic encephalomyelitis
肌痛性脑脊髓炎的内源性逆转录病毒分析
基本信息
- 批准号:10346195
- 负责人:
- 金额:$ 24.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-19 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAnti-Inflammatory AgentsAnti-Retroviral AgentsAntibodiesBedsChronicChronic Fatigue SyndromeComplexDataData SetDiagnostic testsDideoxy Chain Termination DNA SequencingDiseaseEndogenous RetrovirusesExertionExhibitsFDA approvedFamilyFatigueFundingGenesGeneticGenetic TranscriptionGenomicsGenotypeHuman GenomeImmune responseIndividualInfectionInfectious AgentInflammationInflammatoryLeadLinkLocationMalaiseMeasuresMitochondriaModelingMolecularPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhenotypeProductionQuality of lifeReportingRisk FactorsRoleSample SizeSamplingStressTimeTranscriptional ActivationUnited StatesVariantViral GenesVirusVirus DiseasesVirus Integrationbioinformatics toolcase controldeep sequencingdigitaldisabling diseaseexome sequencinggenome sequencinggenome-wideinflammatory markerinnovationpathogensample fixationtooltranscriptometranscriptome sequencingtranscriptomicsviral RNAwhole genome
项目摘要
Project Summary/Abstract
Myalgic encephalomyelitis (ME) is a disabling and complex disease with 1-2.5 million patients in the United
States. ME patients have low quality of life and one in four are bed- or house-bound. ME is under-studied and
under-funded, and there are no existing diagnostic tests, FDA-approved treatments or cure for ME. The causes
of ME are unknown. ME patients exhibit elevated immune responses and enhanced inflammation.
Endogenous retroviruses (ERVs) result from the fixation of ancient retroviral infections and integrations into the
human genome. ERVs (n≈400,000) typically remain silenced; however, some ERVs can be transcriptionally
reactivated. Activated ERVs resemble viral RNA and can therefore trigger immune responses and chronic
inflammation, potentially leading to ME. Together with our collaborators, we have collected the largest deep
sequencing data sets with deep phenotypes from ME patients. We recently developed a set of bioinformatics
tools that allow us to genotype genome-wide individual ERVs and quantify individual ERV expression with high
accuracy. With this R21 application, we propose to use these state-of-the-art tools to analyze existing and new
deep sequencing data to address two Specific Aims. Aim 1: Identify distinct ERVs whose expression is
associated with ME using RNA-Sequencing data. These analyses will, for the first time, quantify transcriptome-
wide expressed ERVs individually; and allow for identification of activated distinct ERVs and ERV genes
associated with ME. Aim 2: Identify ERV variants whose genotypes are associated with ME using whole-
genome sequencing data. These analyses will produce genome-wide distinct ERV genotypes, and, for the first
time, allow for identification of ME-associated individual ERVs and related genes. Upon completion of these
two Aims, we will know whether ERVs and ME are linked at the transcriptomic and/or genomic level.
Elucidating ERVs as risk factors in ME may lead to breakthroughs in ME treatment, such as repurposing
existing FDA-approved anti-retroviral drugs which may reverse ERV effects.
项目总结/摘要
肌痛性脑脊髓炎(ME)是一种致残和复杂的疾病,在美国有1- 250万患者
States. ME患者的生活质量很低,四分之一的患者卧床不起。ME是研究不足的,
资金不足,并且没有现有的诊断测试,FDA批准的治疗或治愈ME。
我是未知的。ME患者表现出升高的免疫应答和增强的炎症。
内源性逆转录病毒(ERV)是由古老的逆转录病毒感染的固定和整合到逆转录病毒中产生的。
人类基因组ERV(n = 400,000)通常保持沉默;然而,一些ERV可以在转录水平上被抑制。
重新激活。活化的ERV类似于病毒RNA,因此可以引发免疫应答和慢性炎症。
炎症,可能导致ME。与我们的合作者一起,我们收集了最大的深度
对来自ME患者的具有深度表型的数据集进行测序。我们最近开发了一套生物信息学
这些工具使我们能够对全基因组个体ERV进行基因分型,并以高水平量化个体ERV表达
精度在这个R21应用程序中,我们建议使用这些最先进的工具来分析现有的和新的
深度测序数据,以解决两个具体目标。目的1:识别表达与ERV相关的不同ERV。
使用RNA测序数据与ME相关。这些分析将首次量化转录组-
单独广泛表达的ERV;并允许鉴定活化的不同ERV和ERV基因
目的2:使用全基因组测序鉴定其基因型与ME相关的ERV变体。
基因组测序数据。这些分析将产生全基因组不同的ERV基因型,
时间,允许鉴定ME相关的个体ERV和相关基因。在完成这些
两个目的,我们将知道ERVs和ME是否在转录组和/或基因组水平上连锁。
阐明ERV作为ME的危险因素可能会导致ME治疗的突破,例如再利用
现有的FDA批准的抗逆转录病毒药物可能逆转ERV的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dawei Li其他文献
Dawei Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dawei Li', 18)}}的其他基金
Comprehensive analyses of endogenous retroviruses with severe chronic fatigue syndrome
内源性逆转录病毒与严重慢性疲劳综合征的综合分析
- 批准号:
10342264 - 财政年份:2021
- 资助金额:
$ 24.08万 - 项目类别:
Endogenous retrovirus analyses in myalgic encephalomyelitis
肌痛性脑脊髓炎的内源性逆转录病毒分析
- 批准号:
10330602 - 财政年份:2021
- 资助金额:
$ 24.08万 - 项目类别:
Comprehensive analyses of endogenous retroviruses with severe chronic fatigue syndrome
内源性逆转录病毒与严重慢性疲劳综合征的综合分析
- 批准号:
9809684 - 财政年份:2019
- 资助金额:
$ 24.08万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 24.08万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 24.08万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 24.08万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 24.08万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 24.08万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 24.08万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 24.08万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 24.08万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 24.08万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 24.08万 - 项目类别: